Achieve Life Sciences, Inc. (ACHV)

NASDAQ: ACHV · IEX Real-Time Price · USD
3.40
+0.10 (3.03%)
Oct 3, 2022 4:30 PM EDT - Market closed
3.03%
Market Cap 32.92M
Revenue (ttm) n/a
Net Income (ttm) -31.88M
Shares Out 9.68M
EPS (ttm) -3.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 9,394
Open 3.38
Previous Close 3.30
Day's Range 3.30 - 3.39
52-Week Range 3.19 - 9.21
Beta 1.19
Analysts Buy
Price Target 32.39 (+852.6%)
Earnings Date Nov 7, 2022

About ACHV

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada. [Read more...]

Industry Biotechnology
CEO Richard Stewart
Employees 16
Stock Exchange NASDAQ
Ticker Symbol ACHV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for ACHV stock is "Buy." The 12-month stock price forecast is 32.39, which is an increase of 852.65% from the latest price.

Price Target
$32.39
(852.65% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation

ORCA-3 Designed to Enable FDA Registration and Confirm the Efficacy and Safety of 3 mg Cytisinicline Three Times Daily Dosing Compared to Placebo in Adult Smokers in the United States ORCA-3 Designed to...

6 days ago - GlobeNewsWire

Achieve Reports Financial Results for Second Quarter 2022 and Provides Corporate Update

Company to host conference call at 4:30 PM EDT today, August 11, 2022 Company to host conference call at 4:30 PM EDT today, August 11, 2022

1 month ago - GlobeNewsWire

Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 11,...

SEATTLE and VANCOUVER, British Columbia, July 28, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development an...

2 months ago - GlobeNewsWire

Achieve Life Sciences Announces Granting of New Hire Inducement Awards

SEATTLE and VANCOUVER, British Columbia, July 01, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commerc...

3 months ago - GlobeNewsWire

Achieve Life Sciences Announces Participation at H.C. Wainwright 1st Annual Mental Health Conference

SEATTLE and VANCOUVER, British Columbia, June 21, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a late-stage clinical pharmaceutical company committed to the global development an...

3 months ago - GlobeNewsWire

Achieve Life Sciences Announces Participation at LD Micro Invitational Conference

SEATTLE and VANCOUVER, British Columbia, May 26, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and comm...

4 months ago - GlobeNewsWire

Achieve Life Sciences Announces Participation at Best Ideas Virtual Investor Conference

SEATTLE and VANCOUVER, British Columbia, May 13, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and comm...

4 months ago - GlobeNewsWire

Achieve Reports Financial Results for First Quarter 2022 and Provides Corporate Update

Company to host conference call at 4:30 PM EDT today, May 12, 2022 Company to host conference call at 4:30 PM EDT today, May 12, 2022

4 months ago - GlobeNewsWire

Achieve Life Sciences Aces Pivotal Cytisinicline Study In Smoking Cessation

Achieve Life Sciences Inc (NASDAQ: ACHV) has announced positive topline results from the Phase 3 ORCA-2 trial of 3mg cytisinicline for 6-weeks or 12-weeks compared to a placebo in 810 adult smokers.  Th...

5 months ago - Benzinga

Achieve Life Sciences to Announce First Quarter Financial Results and Host Conference Call and Webcast on May 12, 2022

SEATTLE and VANCOUVER, British Columbia, April 21, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and co...

5 months ago - GlobeNewsWire

Achieve Life Sciences Announces Appointment of Dr. Vaughn Himes to Board of Directors

SEATTLE and VANCOUVER, British Columbia, March 14, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and co...

6 months ago - GlobeNewsWire

Achieve Life Sciences Announces Expansion of Manufacturing & Quality Operations Team and Granting of Inducement Award

SEATTLE and VANCOUVER, British Columbia, March 11, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and co...

6 months ago - GlobeNewsWire

Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2021 and Provides Corporate Update

Company to host conference call at 4:30 PM EST today, March 10, 2022 Company to host conference call at 4:30 PM EST today, March 10, 2022

6 months ago - GlobeNewsWire

Achieve Life Sciences Announces Participation in March Investor Conferences

SEATTLE, Wash. and VANCOUVER, British Columbia, March 08, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development...

6 months ago - GlobeNewsWire

Achieve Life Sciences Announces Participation in February Investor Conferences

SEATTLE and VANCOUVER, British Columbia, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and com...

8 months ago - GlobeNewsWire

Achieve Life Sciences Initiates Pivotal Trial Of Cytisinicline For Smoking Cessation

Achieve Life Sciences Inc (NASDAQ: ACHV) has initiated the screening in the ORCA-3 Phase 3 trial of cytisinicline for smoking cessation. The trial will evaluate the efficacy and safety of 3 mg cytisinic...

8 months ago - Benzinga

Achieve Life Sciences Announces Initiation of the Phase 3 ORCA-3 Clinical Trial Evaluating Cytisinicline for Smoking ...

SEATTLE and VANCOUVER, British Columbia, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and com...

8 months ago - GlobeNewsWire

Achieve Life Sciences to Present at H.C. Wainwright BIOCONNECT Virtual Conference

SEATTLE, Wash, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisini...

8 months ago - GlobeNewsWire

Achieve Life Sciences Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinic...

Topline ORCA-2 Results Expected in Q2 2022 Topline ORCA-2 Results Expected in Q2 2022

8 months ago - GlobeNewsWire

Achieve Life Sciences Secures $25M Loan Facility To Fund Smoking Cessation Program

Achieve Life Sciences Inc (NASDAQ: ACHV) has entered into a $25 million debt agreement with Silicon Valley Bank and SVB Innovation Credit Fund VIII, L.P.  The proceeds and funds available under the debt...

9 months ago - Benzinga

Achieve Life Sciences Announces $25 Million Loan Facility from Silicon Valley Bank to Fund Cytisinicline Smoking Cess...

SEATTLE and VANCOUVER, British Columbia, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and com...

9 months ago - GlobeNewsWire

Achieve Life Sciences to Host Key Opinion Leader Panel on Smoking and e-Cigarette Cessation

SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development a...

10 months ago - GlobeNewsWire

Achieve Life Sciences Announces Phase 3 ORCA-2 Trial of Cytisinicline in Smoking Cessation Clears Final Review by Dat...

Following the fifth and final DSMC review, committee has concluded no concerns with cytisinicline safety or Phase 3 trial conduct Following the fifth and final DSMC review, committee has concluded no co...

10 months ago - GlobeNewsWire

Achieve Reports Financial Results for Third Quarter 2021 and Provides Update on Cytisinicline Development

SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 09, 2021 (GLOBE NEWSWIRE) -- -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global developmen...

10 months ago - GlobeNewsWire

Achieve Life Sciences Announces Participation in November Investor Conferences

SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development a...

10 months ago - GlobeNewsWire